10:31 ETFood Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsightprnewswire·Jul 27 at 09:32 AMNVS+3.73%RAPT0.00%
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data UpsideTip Ranks·May 18 at 06:05 PMRAPT0.00%
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Sharenasdaq·Mar 15 at 05:35 PMXBI+5.90%GSK+3.38%
Rapt Therapeutics (NASDAQ:RAPT) Receives Average Rating of "Hold" from AnalystsMarket Beat·Mar 5 at 12:44 AMVHT+3.34%XBI+5.90%
RAPT Therapeutics Completes Acquisition and Transitions to Private OwnershipTip Ranks·Mar 3 at 08:37 AMIHE+2.71%IBB+6.58%
Rapt Therapeutics (NASDAQ:RAPT) Sees Large Growth in Short InterestMarket Beat·Feb 13 at 08:41 AMRAPT0.00%SBIO+2.46%
20:02 ETAre RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?prnewswire·Feb 11 at 07:03 PMLSTA-2.61%AVO+1.15%
Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from AnalystsMarket Beat·Feb 8 at 01:38 AMXLV+3.51%VHT+3.34%
Halper Sadeh LLC investigates possible unfair pricing for NWE, DHIL, RAPT shares, offering free consultations to concerned shareholders.Unusual Whales·Feb 6 at 03:32 PMNWE-0.04%SBIO+2.46%
16:29 ETHalper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholdersprnewswire·Feb 6 at 03:30 PMDHIL0.00%RAPT0.00%
Rapt Therapeutics (NASDAQ:RAPT) Hits New 12-Month High - Here's WhyMarket Beat·Feb 5 at 04:39 AMIHE+2.71%PBE+3.13%
GSK profit lifted by HIV, asthma drugs in boost to new CEOBusinesstimes News·Feb 4 at 09:15 AMGSK+3.38%IHE+2.71%
